NCT03290703View on ClinicalTrials.gov

A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

GDC-0853

Participants will receive different formulations of GDC-0853 tablet.

DRUG

Rabeprazole

Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd, Clinical Research Unit, Nottingham

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT03290703 - A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants | Biotech Hunter | Biotech Hunter